Electrocoagulation and curettage has been criticized as inadequate therapy for skin carcinoma. This series of patients demonstrates the effectiveness of electrocoagulation and curettage in the treatment of carcinoma involving the skin of the head and face. From 1964 through 1968, 90 private patients with 128 skin cancers of the head and face were treated by electrocoagulation and curettage. Approximately 50% of these patients were more than 70 years old; 93% of the lesions were basal cell carcinomas and 39% involved the skin of the nose, eyelids, or ears. Forty-four per cent were at least 1 cm or greater in transverse diameter. Only one patient required hospitalization for this therapy, and all lesions were destroyed under local anesthesia. The average healing time was 5.1 weeks. There was neither morbidity nor mortality related to this therapy. All patients were personally followed from 2-7 years. Complete cure was observed in 93% of these lesions. The recurrence rate for 123 primary (previously untreated) skin cancers was 6.5%. Recurrence is first noticed on the scar created by the initial coagulation and is easily recoagulated. These data emphasize the simplicity and adequacy of this treatment modality. In addition, electrocoagulation and curettage is convenient, expeditious, and economical, important assets in these times of burgeoning hospital costs. It is well tolerated by cartilage, and cartilage necrosis has not been observed. Electrocoagulation is tissue-sparing—of great importance in the nose, eye, and ear areas. It avoids anesthetic risks, extensive surgical procedures, prolonged hospitalization, and multiple treatment visits. These considerations justify its use as the preferred therapy of skin cancer of the head and face.